Adult Langerhans cell histiocytosis and immunomodulatory drugs:Review and analysis of thirty-four case reports
Adult Langerhans cell histiocytosis and immunomodulatory drugs:Review and analysis of thirty-four case reports作者机构：Hematology Unit Ca’Foncello Hospital
出 版 物：《World Journal of Hematology》 (世界血液学杂志)
年 卷 期：2019年第8卷第1期
页 面：1-9页
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题：Langerhans cell histiocytosis Immunomodulatory drugs Thalidomide Lenalidomide
摘 要：Langerhans cell histiocytosis(LCH)is a rare neoplastic disease in dendritic *** is classified as either a single-system(SS)or multisystem(MS)*** is not a standard first-line treatment for LCH in *** analyzed the efficacy and safety of immunomodulatory drugs(IMiDs)by searching PubMed/MEDLINE for case reports previously *** clinical response(nonactive disease or active disease that regressed)was 94%in SS and 53%in *** should only be considered for adults with cutaneous SS involvement;in MS,they should be used only for patients not eligible for more aggressive treatments.
维普期刊数据库